Onconova Therapeutics, Inc. to Present New Data on Rigosertib and Earlier-Stage Programs at the 2015 American Association of Cancer Research (AACR) Annual Meeting
April 07, 2015 09:01 ET
|
Onconova Therapeutics
NEWTOWN, Pa., April 7, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Fourth Quarter and Year-End 2014 Financial Results
March 26, 2015 16:01 ET
|
Onconova Therapeutics
NEWTOWN, Pa., March 26, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. to Present at 27th Annual ROTH Conference
March 04, 2015 09:30 ET
|
Onconova Therapeutics
NEWTOWN, Pa., March 4, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Announces Clinical Development Plan for Rigosertib in Higher Risk Myelodysplastic Syndrome (HR-MDS) Patients After Failure of Treatment With Hypomethylating Agents (HMAs)
February 02, 2015 16:01 ET
|
Onconova Therapeutics
Clarity of the design of Phase 3 global replication trial of IV rigosertib in HR-MDS
Updates on development programs for oral rigosertib as a single agent and in combination with azacitidine;...
Onconova Therapeutics, Inc. to Present at Upcoming Investor Conferences in February
January 30, 2015 09:00 ET
|
Onconova Therapeutics
NEWTOWN, Pa., Jan. 30, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Appoints Dr. Steven M. Fruchtman as Chief Medical Officer
January 12, 2015 17:02 ET
|
Onconova Therapeutics
NEWTOWN, Pa., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Announces ONTIME Data Presentations at the 2014 ASH Annual Meeting
December 07, 2014 19:45 ET
|
Onconova Therapeutics
NEWTOWN, Pa., Dec. 7, 2014 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Announces Data Presentation From Combination of Rigosertib and Azacitidine in MDS and Non-proliferative AML at the 2014 ASH Annual Meeting
December 07, 2014 12:01 ET
|
Onconova Therapeutics
NEWTOWN, Pa., Dec. 7, 2014 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics to Host Analyst Event in New York City on December 12, 2014
December 05, 2014 09:00 ET
|
Onconova Therapeutics
NEWTOWN, Pa., Dec. 5, 2014 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. Reports Third Quarter 2014 Financial and Operational Results
November 13, 2014 16:01 ET
|
Onconova Therapeutics
NEWTOWN, Pa., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...